二氯化1,4-二(2-氯乙基)-1,4-二甲基哌嗪二正离子 | 103856-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 二氯化1,4-二(2-氯乙基)-1,4-二甲基哌嗪二正离子
• 中文别名: 3-异丙基-3-氮杂双环[3.3.1]壬烷
• 英文名称: N-Isopropyl-3-aza-bicyclo<3.3.1>nonan
• 英文别名: 3-Azabicyclo[3.3.1]nonane, 3-isopropyl-；3-propan-2-yl-3-azabicyclo[3.3.1]nonane
• CAS: 103856-87-7
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: JQFXLDSKSNUCHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  218.4±8.0 °C(Predicted)
• 密度：
  0.909±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170217974A1

  公开（公告）日：2017-08-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I）或其药学上可接受的盐、酯或前药： X-A-Y-Z-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021154665A1

  公开（公告）日：2021-08-05

  Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

  根据公式I，化合物可用作Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物结合使用，或作为疫苗佐剂。
• BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF
  申请人：Burstein S. Ethan

  公开号：US20070213359A1

  公开（公告）日：2007-09-13

  Disclosed herein are compounds of Formula I as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.

  本文披露了一些公式I定义的化合物，或其药学上可接受的盐，酯，酰胺或前药，该化合物调节胃饥饿素受体的活性。本文还披露了治疗疾病或病症的方法，包括向需要的受试者施用公式I的化合物的治疗有效量。
• HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS
  申请人：AQUINO Christopher Joseph

  公开号：US20090053172A1

  公开（公告）日：2009-02-26

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于治疗CCR5相关的疾病和障碍，例如，用于抑制HIV复制，预防或治疗HIV感染，并用于治疗由此导致的获得性免疫缺陷综合症（AIDS）。
• Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10457703B2

  公开（公告）日：2019-10-29

  The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 所代表的化合物或其药学上可接受的盐、立体异构体、溶液剂、水合物或其组合、 本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。